![Sequentially Determined Measures of Interobserver Agreement (Kappa) in Clinical Trials May Vary Independent of Changes in Observer Performance - Russell Reeve, Klaus Gottlieb, 2019 Sequentially Determined Measures of Interobserver Agreement (Kappa) in Clinical Trials May Vary Independent of Changes in Observer Performance - Russell Reeve, Klaus Gottlieb, 2019](https://journals.sagepub.com/cms/10.1177/2168479019874059/asset/images/large/10.1177_2168479019874059-fig3.jpeg)
Sequentially Determined Measures of Interobserver Agreement (Kappa) in Clinical Trials May Vary Independent of Changes in Observer Performance - Russell Reeve, Klaus Gottlieb, 2019
![ISCT Early Stage Professionals Virtual Career Panel Event: A discussion on different career paths and essential skills required for a career in the cell and gene therapy field. ISCT Early Stage Professionals Virtual Career Panel Event: A discussion on different career paths and essential skills required for a career in the cell and gene therapy field.](https://higherlogicdownload.s3.amazonaws.com/ISCT/UploadedImages/64085pB1Si3MSiBoher5_Career%20pannel%20duo%20graphic.png)
ISCT Early Stage Professionals Virtual Career Panel Event: A discussion on different career paths and essential skills required for a career in the cell and gene therapy field.
Intra-Rater and Inter-Rater Reliability of a Medical Record Abstraction Study on Transition of Care after Childhood Cancer | PLOS ONE
![PDF) Sequentially Determined Measures of Interobserver Agreement (Kappa) in Clinical Trials May Vary Independent of Changes in Observer Performance PDF) Sequentially Determined Measures of Interobserver Agreement (Kappa) in Clinical Trials May Vary Independent of Changes in Observer Performance](https://i1.rgstatic.net/publication/336157529_Sequentially_Determined_Measures_of_Interobserver_Agreement_Kappa_in_Clinical_Trials_May_Vary_Independent_of_Changes_in_Observer_Performance/links/5d94c0c5299bf1c363f2a6a3/largepreview.png)
PDF) Sequentially Determined Measures of Interobserver Agreement (Kappa) in Clinical Trials May Vary Independent of Changes in Observer Performance
Intra-Rater and Inter-Rater Reliability of a Medical Record Abstraction Study on Transition of Care after Childhood Cancer | PLOS ONE
Intra-Rater and Inter-Rater Reliability of a Medical Record Abstraction Study on Transition of Care after Childhood Cancer | PLOS ONE
A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
![Updated Progression-Free Survival and Depth of Response in IKEMA, a randomized phase 3 trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma Updated Progression-Free Survival and Depth of Response in IKEMA, a randomized phase 3 trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma](https://cdn.sanity.io/images/0vv8moc6/onclive/7faa39a46b212c62fcc628c09219aadb8e3e65a7-1264x712.png?fit=crop&auto=format)